ArticleBone marrow transplantation2025
Chronic Graft-versus-Host disease trends over 30 years - a study by the EBMT transplant complications working party.
Article in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evolving Paradigms in Chronic Graft-Versus-Host Disease: From Global Immunosuppression to Precision Targeted and Cell-Based Therapies.Stem cell reviews and reports · 2026Pooled it
- Chronic graft-<I>versus</i>-host disease in the era of posttransplant cyclophosphamide.Haematologica · 2026Article
- [First-line treatment for chronic graft-versus-host disease: a real-world study].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We assessed whether the incidence and outcomes of chronic Graft-versus-Host Disease (cGvHD) after allogeneic hematopoietic stem cell transplantation (alloHSCT) have changed over 30 years. We studied 102,275 adults with hematological malignancies receiving a first alloHSCT from identical siblings or unrelated donors. We compared 3 decades: (I) 1990-1999 vs. (II) 2000-2009 vs. (III) 2010-2019. Over time, patients were older at transplantation, received more PBSC, unrelated donor transplants, reduced intensity conditioning, in vivo T-cell depletion and an ATG prophylaxis, and less TBI. cGvHD incidence at 48 months was 37.3% [36.2-38.4] in I decade vs. 44.9% [44.3-45.5] in II decade vs. 39.1% [38.7-39.5] in III decade, and incidence of extensive cGvHD at 48 months was 18.1% [17.3-19] vs. 22.2% [21.7-22.6] vs. 19.2% [18.9-19.5] over decades. In multivariate analysis, more cGvHD developed in II than in I decade (HR 1.14, 95% CI 1.09-1.21), but no difference was found between III and I decade (HR 1.01, 95% CI 0.96-1.06). Among patients with cGvHD, NRM at 48 months decreased over decades (21.3% [19.8-22.8] vs. 21% [20.3-21.7] vs. 19.7% [19.1-20.2], p < 0.001). Our data show unchanged cGvHD incidences over time and a high NRM in patients after cGvHD diagnosis.
Indexed as
Identifiers
40830236What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.